Objective:To investigate the effectiveness of methylene blue in pain management after costal cartilage removal.Methods:A prospective, randomized controlled trial was conducted from June 2023 to March 2024. Female patients undergoing rhinoplasty with autologous costal cartilage transplantation were randomly divided into a methylene blue group and a control group. Before costal cartilage harvesting, patients in the methylene blue group received a 5 ml injection of 0.1% methylene blue solution into the skin and subcutaneous tissue of the costal cartilage donor site at the lower edge of the seventh costal cartilage or below the breast contour. Patients in the control group received an equal volume of normal saline injected into the same area. Postoperative management included routine observation and pain control (using oral analgesics and topical analgesia). Pain scores were assessed 24 hours after surgery using a visual analog scale (VAS, 0-10 points, higher scores indicate more severe pain) and a numerical rating scale (NRS, 0-10 points, higher scores indicate more severe pain), as well as the frequency of oral analgesics. Patients were followed up for postoperative complications within one month after surgery, and patient satisfaction with pain control was assessed using a self-made 5-point questionnaire (higher scores indicate greater patient satisfaction). Quantitative data were compared between groups using the independent sample t-test; qualitative data were compared between groups using the chi-square test. P<0.05 was considered statistically significant. Results:A total of 112 female patients were enrolled. Fifty-six patients were in the methylene blue group, aged (35.4 ± 5.6) years (range, 18-55 years), and 56 patients were in the control group, aged (36.1 ± 6.0) years (range, 19-54 years). The methylene blue group had significantly lower oral analgesic use 24 hours after surgery than the control group [(1.5±0.5) times vs. (4.7±1.2) times], with statistically significant differences ( P<0.05). The methylene blue group also had significantly lower VAS scores (3.2±1.2 vs. 5.8±1.3) and NRS scores (3.5±1.0 vs. 6.2±1.1) 24 hours after surgery than the control group ( P<0.05). At one-month follow-up, the incidence of postoperative complications in the methylene blue group was significantly lower than that in the control group [10.7% (6/56) vs. 21.4% (12/56)]. Patient satisfaction in the methylene blue group was significantly higher than that in the control group [4.5 ± 0.6 vs. 3.2 ± 0.8]. The differences were statistically significant ( P< 0.05). No serious adverse reactions were observed in either group. Conclusion:Methylene blue has a good analgesic effect after costal cartilage transplantation, reducing the need for analgesics, and no significant adverse reactions were observed.

Objective:To investigate the effectiveness of methylene blue in pain management after costal cartilage removal.Methods:A prospective, randomized controlled trial was conducted from June 2023 to March 2024. Female patients undergoing rhinoplasty with autologous costal cartilage transplantation were randomly divided into a methylene blue group and a control group. Before costal cartilage harvesting, patients in the methylene blue group received a 5 ml injection of 0.1% methylene blue solution into the skin and subcutaneous tissue of the costal cartilage donor site at the lower edge of the seventh costal cartilage or below the breast contour. Patients in the control group received an equal volume of normal saline injected into the same area. Postoperative management included routine observation and pain control (using oral analgesics and topical analgesia). Pain scores were assessed 24 hours after surgery using a visual analog scale (VAS, 0-10 points, higher scores indicate more severe pain) and a numerical rating scale (NRS, 0-10 points, higher scores indicate more severe pain), as well as the frequency of oral analgesics. Patients were followed up for postoperative complications within one month after surgery, and patient satisfaction with pain control was assessed using a self-made 5-point questionnaire (higher scores indicate greater patient satisfaction). Quantitative data were compared between groups using the independent sample t-test; qualitative data were compared between groups using the chi-square test. P<0.05 was considered statistically significant. Results:A total of 112 female patients were enrolled. Fifty-six patients were in the methylene blue group, aged (35.4 ± 5.6) years (range, 18-55 years), and 56 patients were in the control group, aged (36.1 ± 6.0) years (range, 19-54 years). The methylene blue group had significantly lower oral analgesic use 24 hours after surgery than the control group [(1.5±0.5) times vs. (4.7±1.2) times], with statistically significant differences ( P<0.05). The methylene blue group also had significantly lower VAS scores (3.2±1.2 vs. 5.8±1.3) and NRS scores (3.5±1.0 vs. 6.2±1.1) 24 hours after surgery than the control group ( P<0.05). At one-month follow-up, the incidence of postoperative complications in the methylene blue group was significantly lower than that in the control group [10.7% (6/56) vs. 21.4% (12/56)]. Patient satisfaction in the methylene blue group was significantly higher than that in the control group [4.5 ± 0.6 vs. 3.2 ± 0.8]. The differences were statistically significant ( P< 0.05). No serious adverse reactions were observed in either group. Conclusion:Methylene blue has a good analgesic effect after costal cartilage transplantation, reducing the need for analgesics, and no significant adverse reactions were observed.

Stem cell exosome therapy has shown significant potential in treating hair loss, but its safety profile has not been thoroughly studied. This paper reported a case of a 32-year-old female patient who experienced an allergic reaction following adipose-derived stem cell exosomes injection for hair loss treatment at the Plastic Surgery Hospital, Chinese Academy of Medical Sciences in June 2023. Within 24 hours post-injection, the patient developed swelling of the forehead and right postauricular lymph nodes, accompanied by mild pain, and left posterior ear lymph nodes 48 hours later. Ultrasound examination revealed thickening of the local soft tissue and enlarged lymph nodes. The condition was diagnosed as an injection-induced allergic reaction. The symptoms gradually subsided after combined treatment with lidocaine, 5-fluorouracil, and triamcinolone acetonide injections. During a 6-month follow-up period, the patient did not experience any recurrence of allergic reactions, and the therapeutic effects remained stable. This case report highlights the potential risk of allergic reactions associated with stem cell exosome therapy for hair loss, underscoring the need for close monitoring and timely intervention in clinical applications to ensure both safety and efficacy.

Stem cell exosome therapy has shown significant potential in treating hair loss, but its safety profile has not been thoroughly studied. This paper reported a case of a 32-year-old female patient who experienced an allergic reaction following adipose-derived stem cell exosomes injection for hair loss treatment at the Plastic Surgery Hospital, Chinese Academy of Medical Sciences in June 2023. Within 24 hours post-injection, the patient developed swelling of the forehead and right postauricular lymph nodes, accompanied by mild pain, and left posterior ear lymph nodes 48 hours later. Ultrasound examination revealed thickening of the local soft tissue and enlarged lymph nodes. The condition was diagnosed as an injection-induced allergic reaction. The symptoms gradually subsided after combined treatment with lidocaine, 5-fluorouracil, and triamcinolone acetonide injections. During a 6-month follow-up period, the patient did not experience any recurrence of allergic reactions, and the therapeutic effects remained stable. This case report highlights the potential risk of allergic reactions associated with stem cell exosome therapy for hair loss, underscoring the need for close monitoring and timely intervention in clinical applications to ensure both safety and efficacy.

Objective:To explore the HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy (ART) in Taizhou city.Methods:A cross-sectional study of HIV-1 drug resistance was conducted among newly reported HIV/AIDS patients before ART in Taizhou from January 2016 to December 2018. HIV-1 pol gene sequences were obtained by RT-PCR. The sequences were submitted to the Stanford University drug resistance database. The drug resistance mutation and the sensitivity of HIV-1 strains to antiretroviral drugs were determined according to WHO Guidelines on HIV drug resistance surveillance of 2014. Results:A total of 806 HIV-1 pol gene sequences were obtained successfully. The overall HIV-1 drug resistance rate was 2.9% (23/806), 1.9% for non-nucleoside reverse transcriptase inhibitors (NNRTIs), 0.6% for nucleoside reverse transcriptase inhibitors (NRTIs), and 0.0% for protease inhibitors (PIs), respectively. From 2016 to 2018, the HIV-1 drug resistance rate was 1.6%, 1.8%, and 4.8%, respectively. The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%). HIV-1 subtypes were mostly CRF01_AE (42.7%,344/806),CRF07_BC (28.9%,233/806) and CRF08_BC (11.2%,90/806).HIV-1 subtypes among homosexually transmitted infections were mostly CRF01_AE (53.3%, 136/255) and CRF07_BC (32.2%, 82/255), and HIV-1 subtypes among heterosexually transmitted infections were mainly CRF01_AE (37.7%, 203/539), CRF07_BC (27.5%, 148/539) and CRF08_BC (16.1%, 87/539). Conclusion:HIV-1 drug resistance rate among newly reported HIV/AIDS patients before ART remained low in Taizhou during 2016 to 2018, an increasing trend seemed to be notifiable and warrants continuous surveillance of HIV-1 drug resistance.

Objective To investigate the risky sexual behaviors,associated factors and characteristics of sexual network among clients receiving methadone maintenance treatment (MMT) at the clinics in Taizhou prefecture of Zhejiang province.Methods A cross-sectional survey was conducted.Data was collected through questionnaire and from the national unified MMT system.Urine was collected to test heroin,methamphetamine,3,4-methylenedioxymethamphetamine (MDMA) and ketamine.Blood was collected to test infections on HIV,hepatitis C vims(HCV) and syphilis.Results Totally,362 clients were recruited.Most of the clients were male (88.7％),31--40 year-olds (54.5％),married (61.6％) and having received junior high school education (56.6％).85.1％ of them received urine test with 82(26.6％) positive for heroin,21 (6.8％) positive for methamphetamine,19 (6.2％) positive for MDMA and none for ketamine.77.1％ of them received blood test,and prevalence rates for HIV,HCV and syphilis were 1.1％,36.7％ and 3.6％.19.5％ of the clients who had sex in the past 6 months.Factors as having multiple sexual partners and positive for club drugs were under higher risk.Sexual networking seemed to be loose,linear and acyclic among this population but overlapping with the drug-using network.Conclusion Effective and targeted interventions should be taken among the MMT clients since continuing drug use and HIV/STD related sexual behavior were found common in them,suggesting there was a risk of HIV/STD transmission in this ppulation.

Objective To examine the prevalence and correlates of hepatitis C virus (HCV) co-infection as well as plasma HCV viral load among newly diagnosed HIV-infected adults during 2009-2012 in Taizhou prefecture of Zhejiang province,China.Methods Five hundred and seventy-two adults who were newly diagnosed as HIV-infection were screened for anti-HCV immunoglobulin G (IgG).Plasma HCV RNA was quantified if positive for HCV IgG.Results Forty-two (7.3％) out of the 572 HIV-infected adults were tested positive for HCV IgG.HCV infection was more likely to occur among participants who were infected with HIV through blood transmission (OR=49.46,95％CI:13.71-178.48).Otherwise,HCV infection was less likely to occur among participants who were under 46-86 years of age (OR=0.12,95％CI:0.02-0.58),those with mode of homosexual transmission of HIV (OR=0.11,95％ C I:0.01-0.86),with education of high school or above (OR=0.13,95％ CI:0.02-0.78).Thirty-three (78.6％) of the total 42 HIV-HCV patients with coinfection had detectable plasma HCV RNA,whereas 9 (21.4％) had undetectable plasma HCV RNA (i.e.,lower than 5.0 × 102 IU/ml) or known as relative HCV viral suppression.No significant associations were noticed on factors as:HCV viral suppression and demographics,HIV transmission route and CD4 + T-cell counts according to univariate regression analyses.Conclusion Prevalence of HCV co-infection was relatively high among newly diagnosed HIV-infected adults in this study area.Majority of the HIV-HCV coinfected patients had detectable plasma HCV RNA,of which the long term impact on disease progression deserves called for further research.